Indian Generics Also Suffer Slowdown In U.S. Economy
This article was originally published in PharmAsia News
New data suggests Indian generics makers suffered to a large extent in the downturn in the U.S. economy in 2008. According to IMS Health Retail Drug Monitor, drugstore sales in the United States grew by only one percent last year, an important figure since the country accounts for half of the global pharmaceutical market. But generics makers are expected to profit in general because a weaker economy leads to greater emphasis on generics over branded drugs. The large European market rose by two percent during the period ending in October of last year and emerging markets demonstrated a better growth in sales. (Click here for more
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.